

# Jeremy A Rassen Scd

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9273743/jeremy-a-rassen-scd-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 papers	4,935 citations	35 h-index	70 g-index
77 ext. papers	5,939 ext. citations	5.1 avg, IF	5.54 L-index

#	Paper	IF	Citations
69	Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e222959	10.4	3
68	The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 111, 135	6.1	2
67	COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. <i>PLoS ONE</i> , <b>2021</b> , 16, e0248128	3.7	4
66	Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 672-679	11.5	120
65	Reply to the Letter by Arterburn D. et al. ("Bias in EHR-based studies: Seeing the Forest for the Trees"). <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1694-1695	6.7	
64	Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study. <i>Cmaj</i> , <b>2021</b> , 193, E10-E18	3.9	22
63	Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1453-1462	6.7	7
62	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 816-828	6.1	3
61	Single-arm oncology trials and the nature of external controls arms. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 1052-1066	2.1	2
60	Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile. <i>Drugs - Real World Outcomes</i> , <b>2020</b> , 7, 221-227	2.2	1
59	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. <i>Science</i> , <b>2020</b> , 370,	33.3	261
58	Graphical Depiction of Longitudinal Study Designs in Health Care Databases. <i>Annals of Internal Medicine</i> , <b>2019</b> , 170, 398-406	8	58
57	Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2019</b> , 25, 1442-1452	1.9	6
56	Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. <i>Clinical Epidemiology</i> , <b>2019</b> , 11, 1-15	5.9	40
55	Effects of expanding the look-back period to all available data in the assessment of covariates. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 890-899	2.6	24
54	Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. <i>Epidemiology</i> , <b>2017</b> , 28, 237-248	3.1	36
53	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , <b>2017</b> , 20, 1009-1022	3.3	47

52	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1018-1032	2.6	78
51	Incorporating linked healthcare claims to improve confounding control in a study of in-hospital medication use. <i>Drug Safety</i> , <b>2015</b> , 38, 589-600	5.1	5
50	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. <i>Drug Safety</i> , <b>2015</b> , 38, 1075-82	5.1	7
49	High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions. <i>Statistics in Medicine</i> , <b>2015</b> , 34, 753-81	2.3	31
48	Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. <i>Drug Safety</i> , <b>2014</b> , 37, 151-61	5.1	13
47	Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. <i>Computational Statistics and Data Analysis</i> , <b>2014</b> , 72, 219-226	1.6	60
46	Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large-scale studies. <i>Epidemiology</i> , <b>2014</b> , 25, 126-33	3.1	14
45	Optimal matching ratios in drug safety surveillance. <i>Epidemiology</i> , <b>2014</b> , 25, 772-3	3.1	6
44	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 619-27	2.6	20
43	Metrics for covariate balance in cohort studies of causal effects. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 1685-99	2.3	145
42	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1813-8	2.4	43
41	Cardiovascular risk in rheumatoid arthritis: comparing TNF-blockade with nonbiologic DMARDs. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 730.e9-730.e17	2.4	72
40	Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2013</b> , 146, 472-8	1.5	10
39	Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. <i>BMJ, The</i> , <b>2013</b> , 347, f5416	5.9	52
38	Confounding adjustment in comparative effectiveness research conducted within distributed research networks. <i>Medical Care</i> , <b>2013</b> , 51, S4-10	3.1	43
37	Matching by propensity score in cohort studies with three treatment groups. <i>Epidemiology</i> , <b>2013</b> , 24, 401-9	3.1	103
36	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. <i>BMC Medical Research Methodology</i> , <b>2012</b> , 12, 180	4.7	24
35	Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. <i>Drug Safety</i> , <b>2012</b> , 35, 407-16	5.1	10

34	Design considerations in an active medical product safety monitoring system. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21 Suppl 1, 32-40	2.6	35
33	Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21 Suppl 1, 41-9	2.6	70
32	Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 697-709	2.6	53
31	An event-based approach for comparing the performance of methods for prospective medical product monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 631-9	2.6	10
30	Response to commentary by Marcus and Gibbons. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 713-2.6		
29	Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21 Suppl 2, 90-8	2.6	10
28	One-to-many propensity score matching in cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21 Suppl 2, 69-80	2.6	253
27	Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. <i>Epidemiology</i> , <b>2012</b> , 23, 238-46	3.1	27
26	Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. <i>Circulation: Cardiovascular Interventions</i> , <b>2012</b> , 5, 590-6	6	28
25	Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. <i>European Heart Journal</i> , <b>2012</b> , 33, 1893-901	9.5	137
24	Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 80-6	6.1	39
23	Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 777-90	6.1	137
22	Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 675-83	2.6	19
21	Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 1199-209	2.6	28
20	Re: Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 1110-1; author reply 1112	2.6	6
19	Effects of adjusting for instrumental variables on bias and precision of effect estimates. <i>American Journal of Epidemiology</i> , <b>2011</b> , 174, 1213-22	3.8	163
18	Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. <i>American Journal of Epidemiology</i> , <b>2011</b> , 173, 1404-13	3.8	132
17	Myers et al. Respond to "Understanding Bias Amplification". <i>American Journal of Epidemiology</i> , <b>2011</b> , 174, 1228-1229	3.8	20

16	The comparative safety of analgesics in older adults with arthritis. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 1968-76		282
15	The comparative safety of opioids for nonmalignant pain in older adults. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 1979-86		172
14	Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2010</b> , 31, 561-72	9.5	47
13	Confounding control in healthcare database research: challenges and potential approaches. <i>Medical Care</i> , <b>2010</b> , 48, S114-20	3.1	237
12	Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. <i>Medical Care</i> , <b>2010</b> , 48, S83-9	3.1	25
11	Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 848-57	2.6	37
10	Instrumental variable methods in comparative safety and effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 537-54	2.6	229
9	Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. <i>Circulation</i> , <b>2009</b> , 120, 2322-9	16.7	177
8	High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. <i>Epidemiology</i> , <b>2009</b> , 20, 512-22	3.1	712
7	Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. <i>Journal of Clinical Epidemiology</i> , <b>2009</b> , 62, 1226-32	5.7	123
6	Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. <i>Journal of Clinical Epidemiology</i> , <b>2009</b> , 62, 1233-41	5.7	91
5	Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. <i>American Journal of Epidemiology</i> , <b>2009</b> , 169, 273-84	3.8	114
4	Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects?. <i>Medical Care</i> , <b>2007</b> , 45, S116-22	3.1	45
3	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 3390-8		74
2	Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US		5
1	Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine		9